NAD metabolism
Human evidence and active trials are visible in this field
12 human-evidence records · 6 active trials · 27 visible funding records · 7,646 universities
Australian Patent Application
eNAMPT INCREASING AGENT SIRTUIN ACTIVATION OR EXPRESSION ENHANCER NAD INCREASING AGENT AND SENESCENT CELL INHIBITOR
Source-linked patent metadata for eNAMPT INCREASING AGENT SIRTUIN ACTIVATION OR EXPRESSION ENHANCER NAD INCREASING AGENT AND SENESCENT CELL INHIBITOR, including priority, record stage and longevity-topic connections.
Australian application snapshot
Patent application record
This privacy-minimal view describes one official Australian patent application record. It is not presented as a complete worldwide patent family.
- Application number
- AU2023254626
- Earliest priority
- April 13, 2022
- Application date
- November 13, 2024
- Source record
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Senolytics
Human evidence and active trials are visible in this field
198 human-evidence records · 12 active trials · 872 visible funding records · 7,604 universities
Sirtuins
Human evidence and active trials are visible in this field
10 human-evidence records · 1 active trials · 43 visible funding records · 6,699 universities
Why names are absent
This feed intentionally excludes party names and contact details to minimise personal data. Open the official record when a name is consequential.
Topics connected by metadata
How the patent office classifies this invention
A23L19/00 · A23L33/175 · A61K31/198 · A61P43/00
Verify in the original patent source →